Background The survival of colorectal cancer patients is frequently determined by the extent
of metastatic invasion to the liver; in cases of major involvement, therapeutic strategies are …

The liver is the dominant site of metastases for patients with metastatic colorectal cancer
(mCRC). Depending on the timing of diagnosis and the biology of the disease, it is not …

Introduction The liver is the most frequent site of metastases from colorectal cancer (CRC),
and extensive liver metastases often cause severe secondary liver dysfunction. However …

It is not the most intellectual of the species that survives; it is not the strongest that survives;
but the species that survives is the one that is able best to adapt and adjust to the changing …

Colorectal cancer remains one of the most common cancers worldwide. The treatment of
metastatic disease has advanced considerably in the past 10 years both in terms of surgical …

Metastatic colorectal cancer remains a public-health issue on a global scale. With
development of a new generation of cytotoxic agents, survival has improved for patients with …

Aim Hepatic toxicity of chemotherapy for colorectal cancer and its complications after hepatic
metastasis surgery are unclear. Studies reporting hepatic lesions after chemotherapy for …

Colon cancer patients with severe hepatic dysfunction secondary to liver metastases have
limited treatment options. 5-Fluorouracil (5-FU) infusional therapy has been attempted, but …

For over 40 years, fluorouracil has been the only drug registered for the treatment of
metastatic colorectal cancer. During the past 5 years, combination chemotherapy regimens …

There are many novel chemotherapeutic options and targeted therapies available for the
treatment of colorectal and pancreatic cancer. Patients with these cancers often have …